Amplification or duplication of the AML1 gene at chromosome band 21q22 was detected by FISH using a locus-specific probe in three out of 171 unselected patients with therapy-related myelodysplasia (t-MDS) or t-AML (1.7%). In two patients AML1 signals were located tandemly on derivative chromosomes, in one patient on a dic(9;21) and in the the other patient on a derivative chromosome 18 made up of interchanging layers of material from chromosomes 9, 14, 18, and 21. In the third patient three single supernumerary copies of AML1 were located on derivatives of chromosomes 19 and 21. All three patients were older, had previously received therapy with alkylating agents without topoisomerase II inhibitors, had complex karyotypes including abnormalities of chromosomes 5 or 7, and presented acquired point mutations of the TP53 gene. No point mutations of the AML1 gene were observed. The results support a pivotal role of impaired TP53 function in the development of gene amplification or duplication in t-MDS and t-AML.
Introduction
The AML1 gene located at chromosome band 21q22 encodes one of the two subunits of the human core binding factor (CBF), which regulates the expression of several genes essential to normal hematopoiesis. 1 In acute leukemia three types of abnormality of AML1 have been observed. Most frequently, AML1 is disrupted by recurrent reciprocal chromosome translocations with formation of new chimeric oncogenes with a pivotal role in leukemogenesis. 2, 3 The second type of abnormality is point mutations of AML1, observed in de novo myelodysplasia (MDS) and acute myeloid leukemia (AML), 4 and in therapy-related MDS (t-MDS) significantly associated with previous therapy with alkylating agents, with deletion or loss of chromosome arm 7q, and with subsequent progression to t-AML. 5 The third type of abnormality of AML1 in leukemia is amplification or duplication of the unrearranged gene. This phenomenon has been observed in approximately 2% of patients with childhood acute lymphoblastic leukemia (ALL), [6] [7] [8] [9] but to our knowledge only in seven cases of de novo MDS and AML. [10] [11] [12] [13] [14] [15] In these seven patients the mutational status of TP53 was not examined. In t-MDS and t-AML a similar amplification or duplication of chromosome band 11q23 including the unrearranged MLL gene has been observed in 17% of the patients closely associated with mutations of the TP53 gene. 16 As also AML1 amplification could be more common in t-MDS and t-AML than in de novo disease, we performed FISH for amplification or duplication of AML1 in 171 cases of t-MDS and t-AML, and examined positive cases for mutations of TP53.
Materials and methods

Patients and cytogenetics
Bone marrow cells of 171 unselected patients with t-MDS/t-AML were obtained at diagnosis and stored in methanol-acetic acid at À201C. The G-banded karyotypes of 128 of the patients have been published, 17 whereas the karyotypes of the remaining 43 cases are unreported.
FISH analyses
FISH analyses were performed as recommended by the manufacturer using a locus-specific TEL/AML1 probe (Vysis (Downers Grove, IL, USA), and various whole-chromosome and centromere-specific probes (Vysis). M-FISH was performed in cases I-III (Spectra Vision probes, Vysis). Signals were visualized by an epiflourescence microscope (Zeiss Axioscop, Oberkochen, Germany), and images captured by the Quips Smart Capture FISH Imaging Software (Vysis) and Applied Imaging Cytovision Workstation (Newcastle, UK). Cases were classified as AML1 amplification or duplication, if, per metaphase cell, two or more signals were located on the same chromosome arm, or if two or more extra single signals of AML1 were detected on different chromosome arms. Cases with extra copies of AML1 solely due to gain of whole extra chromosomes 21 were not considered.
Mutations of TP53 and AML1
Mutations of TP53 were searched for by direct sequencing of TP53 exons 2-10, and mutations of AML1 were searched for by direct sequencing of exons 3-8 as previously described.
5,18.
Results and discussion
Three out of 171 unselected patients (1.7%) with t-MDS and t-AML presented 4-6 copies of AML1 per cell confirming that amplification of AML1 is a rather rare phenomenon in myeloid malignancies. [10] [11] [12] [13] [14] [15] Patient characteristics, karyotypes, results of FISH, and mutation status of TP53 and AML1 of the three cases are shown in Table 1 .
Patient I disclosed four or five apparently normal copies of AML1 all located on a dic(9;21) ( Figure 1a ). Using M-FISH and whole-chromosome painting probes it was shown that material 
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translocated to chromosome band 21q22 consisted of small interspersed layers of material from 9p and 21q, including the 4-5 copies of AML1 inserted between 9p24 and 21q22 ( Figure 1b) . Patient II disclosed four or five apparently normal copies of AML1 on a derivative of chromosome 18 made up of small layers of material from chromosomes 18, 9, 14, and 21 ( Figure  1c and d) . In some cells, material from chromosome 9 could not be identified on the der (18) . The extra copies of AML1 were interspersed between material from chromosome 14 (Figure 1d) .
Patient III disclosed four apparently normal copies of AML1 on different chromosome arms: One copy was on the normal chromosome 21, another was located on a der (19) to which a segment of 21q was translocated, and two copies were located on a der(21) to which material from chromosome 19 was inserted between two segments of 21q each containing a copy of AML1 (Figure 1e and f) . In addition, five copies of AML1 were detected in a large proportion of interphase cells.
A mutation of TP53 was detected in all three patients. Patient A had a 734G-A base change resulting in a G245D aminoacid substitution, patient B had a IVS5-2 A-C base change resulting in disruption of a splice site, and patient C had a 731G-T base change resulting in a G245V amino-acid substitution (Table 1) . Similar to what has been reported in childhood ALL, 19 point mutations of AML1 were not detected in any of the three patients.
The three patients with amplification or duplication of AML1 observed in the present study share striking similarities; all three patients were older, had previously received therapy with alkylating agents, had very complex karyotypes, and presented mutations of TP53.
The mechanisms underlying gene amplification in cancer are far from solved. DNA breakage followed by breakage-fusion bridge formation is one suggested mechanism, 20 and experimental studies have demonstrated that mutational inactivation of TP53 is associated with gene amplification and aneuploidy. 21, 22 The results of our previous study 18 and of the present study support and important role of TP53 mutations in gene amplification and duplication as 10 out of 11 patients with amplification or duplication of MLL or AML1 presented TP53 mutations. The excess of patients with amplification or duplication of MLL or AML1 following therapy with alkylating agents could relate to a double effect of these drugs, that is, DNA breakage and induction of mutation of TP53.
So far only few studies have evaluated the genetic consequences of amplification or duplication of the MLL and AML1 genes. In 31 patients with MDS or AML and gain of 11q23, Poppe et al 23 demonstrated by real-time quantitative RT-PCR increased expression of the unrearranged MLL gene in parallel with an increasing number of MLL copies. The overexpression of MLL apparently resulted in a gain of function, as it was associated with increased expression of HOXA9, a downstream target of MLL. 23 Similarly, Mikhail et al 24 detected enhanced AML1 expression in nine patients with ALL and extra copies of AML1. Five of these patients had only a nonconstitutional trisomy 21 and four patients had tandem copies of AML1 on a der (21) . Experimentally, overexpression of the unrearranged AML1 gene has been shown to have oncogenic potential. 25 Surprisingly, in the study by Mikhail et al, 24 also nine out of the remaining 32 patients without amplification of AML1 showed overexpression of the gene suggesting that other mechanisms than gene amplification may be involved in overexpression of AML1.
The often rather large size of the amplified regions on 21q has raised the question whether other genes in the proximity of AML1 could be of importance. Recently, amplification of 21q was shown to result in overexpression of other genes than AML1 located to 21q such as the APP, the ETS2, and the ERG genes. 26 The present study strongly confirms and extends a close association between mutation of TP53 and chromosomal instability underlying amplification of chromosome bands 11q23 and 21q22. It is of interest that mutations of TP53 and complex karyotypes are also very common in many solid tumors. (19) , and two AML1 signals on the der(21).
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